In the News Archive
- 2016-08-01 - Takeda and Seattle Genetics announce positive data from trial for cutaneous T-cell lymphoma
- 2016-08-01 - MEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination with Azacitidine of Patients with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Chemotherapy
- 2016-06-17 - Merck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer
- 2016-06-08 - Kite Pharma to Highlight Key Data from CAR T-Cell Therapy Pipeline in Oral Presentations at the 2016 European Hematology Association (EHA) Annual Congress
- 2016-06-06 - Immunotherapy Improves Survival, Quality of Life in Rapidly Progressing Head and Neck Cancer
- 2016-06-06 - Pembrolizumab Elicits Significant Antitumor Activity in Advanced Head and Neck Cancer Patients
- 2016-06-04 - New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
- 2016-06-04 - Bristol-Myers’s Drug Combination Boosts Lung Cancer Benefit
- 2016-05-31 - ASCO Value Framework Update
- 2016-05-24 - Immunotherapy may aid ovarian cancer chemotherapy resistance, study suggests
- 2016-05-18 - FDA approves new, targeted treatment for bladder cancer
- 2016-05-18 - Merck, Bristol drugs show longer survival for deadly cancers
- 2016-05-18 - German Merck, Pfizer immunotherapy shows promise in rare skin cancer
- 2016-05-18 - Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer
- 2016-05-16 - New cancer immunotherapy approach combines tumor fighting power with fewer side effects, study shows